ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Budget 2023
  • Markets
    • Stocks
    • Global Markets
    • IPO
    • Companies
    • Currency
    • Commodities
  • My Money
  • Calculators
    • Income Tax Calculator
    • Home Loan/EMI Calculator
    • Mutual Fund Returns Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • SIP calculator
    • Lumpsum Calculator
    • SWP Calculator
  • Videos
    • M Se Market
    • Jeb Zindagi Zaroorat
    • Light Camera Stocks
    • Tech Takes
    • Big Bulls Ka Nishana
    • Paisa Wasool
    • Commodity Ke MrityunjayMantra
    • The Right Property Show
  • Economy & Infra
    • Policy & Initiatives
    • Agriculture
    • Telecom
    • Aviation
    • Railways
    • Retail
    • Roadways
    • World Economy
  • Exclusive
    • Wealth Guide
    • Interviews
  • Auto
    • Cars
    • Bikes
    • Electric Vehicle
    • Commercial Vehicles
  • Tech
    • Mobiles
    • Gadgets
    • Reviews
    • Tips and Tricks
    • Apps
  • Start ups
    • Funding
    • Appointments
  • Real Estate
    • Home Buyers
    • Builders
  • Axis MF
  • Trending
    • Entertainment
    • Politics
    • Lifestyle
    • Travel
    • Sports
    • Viral
    • Education
    • Jobs
Read in App
Business News » Companies News

Sun Pharma to acquire oncology product from Novartis for $175 million; stock up 0.5%

"Odomzo gives us an opportunity to meaningfully expand our already established branded dermatology business and support our expansion into branded oncology with a launched brand," Kirti Ganorkar, Global Head Business Development at Sun Pharma, said.

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Sun Pharma to acquire oncology product from Novartis for $175 million; stock up 0.5%
BSE. Representational image. Pic: IANS

Drug major Sun Pharmaceutical Industries today said it it will acquire a branded oncology product, Odomzo, from Novartis for an upfront payment of USD 175 million.

The agreement has been signed between subsidiaries of both the companies and will close following anti-trust clearance and further closing conditions, the Mumbai-based company said in a statement.

The agreement has been signed for an upfront payment of USD 175 million and additional milestone payments, it added.

"Odomzo gives us an opportunity to meaningfully expand our already established branded dermatology business and support our expansion into branded oncology with a launched brand," Kirti Ganorkar, Global Head Business Development at Sun Pharma, said.

The company sees meaningful global potential for Odomzo by leveraging Sun Pharmas existing dermatology and oncology infrastructure to provide an innovative product to patients worldwide, he added.

Odomzo was approved by the USFDA in July 2015. It is indicated for the treatment of adult patients with locally advanced basal cell carcinoma.

Sun Pharma shares were trading 0.52 per cent up at Rs 617.60 apiece on BSE. 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Sun PharmaNovartisacquisitionPharmapharmaceuticalSun Pharma share priceSun Pharma Stock PriceOdomzo
Written By: PTI
Updated: Thu, Dec 22, 2016
02:21 pm
New Delhi, PTI
RELATED NEWS
Top Gainers & Losers: UltraTech results disappoint Street, Sun Pharma, Hindustan Unilever rise Top Gainers & Losers: UltraTech results disappoint Street, Sun Pharma, Hindustan Unilever rise
Budget 2023 Expectation: Pharma, healthcare industry seek simplified regulations, research-based incentives Budget 2023 Expectation: Pharma, healthcare industry seek simplified regulations, research-based incentives
Should you buy, sell or hold IndusInd, ITC, Titan, Sun Pharma today? What brokerages say Should you buy, sell or hold IndusInd, ITC, Titan, Sun Pharma today? What brokerages say
Sun Pharma's Halol worries persist as US drug regulator pulls up pharma major for lapses Sun Pharma's Halol worries persist as US drug regulator pulls up pharma major for lapses

LATEST NEWS

Pathaan box office collection: Shah Rukh Khan-starrer breaks all records — Check collection figures of SRK's last 5 films

Need to help India find alternatives to Russian military equipment: Biden admin tells lawmakers

NTPC Q3 Results: Net profit jumps nearly 5% YoY to Rs 4,854 cr; company announces dividend

Adani Group rules out changes in price, dates of FPO; company confident offer share sales going through

Equity mutual fund will move to shorter redemption payment cycle of T+2 from February 1

BEL Dividend 2023 News: Check amount, record date and ex date

Piyush Goyal calls for creation of network of mentors, investors, entrepreneurs to strengthen start-up ecosystem

Adani Group-Hindenburg: What options Adani Group have? Anil Singhvi decodes

Vande Bharat Viral Garbage Photo: Railway Minister directs authorities to change cleaning system in Vande Bharat trains, seeks cooperation from people

Hi-Tech Pipes declares stock split: Check ratio and record date

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2023. India Dot Com Private Limited. All Rights Reserved.
LIVE TV